The National Association of Chain Drug Stores commented on the proposed regulations on the use of managed care in Medicaid and in the Children’s Health Insurance Program, urging "to maintain the strong link between Medicaid patients and community pharmacies and the valuable services that these pharmacies provide."
In late July, the Government Accountability Office released a report on how the lack of effective communications between the Drug Enforcement Agency and both pharmaceutical distributors and chain pharmacy headquarters has impacted legitimate access to pain medicines. "The agency’s report further validates the need for bipartisan, bicameral legislation," according to NACDS.
Hair care brand Alberto VO5 on Thursday declared August its third annual “National Anti-Frizz Month,” offering frizz-taming advice and savings on frizz products via the brand’s website and social media channels.
The Consumer Healthcare Products Association expressed support for the DXM Abuse Prevention Act, introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson, R-Ohio, and Doris Matsui, D-Calif., on Wednesday.
The DEA announced on Tuesday that the 10th National Prescription Drug Take-Back will take place across the United States on Sept. 26 — except for in Pennsylvania and Delaware where the event will take place on Sept. 12.
Voters from all political parties support sunshine legislation that would make promote transparency in generic prescription drug payments by pharmacy benefit manager corporations, according to a national survey from the National Community Pharmacists Association released Tuesday.
Sandoz on Tuesday announced the launch of a generic version of AstraZeneca’s Pulmicort Respules (budesonide inhalation suspension) in 1-mg strength. Sandoz expects to have 180-day generic drug marketing exclusivity for the 1-mg strength.
The Israeli Health Ministry approved on Monday a decision to allow patients licensed to receive medical marijuana from a pharmacy with authorization from a medical expert, according to theJerusalem Post.
The Food and Drug Administration announced Friday that it approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and cirrhosis.
A new coalition has formed to ensure safe access to over-the-counter pain relief remedies. The Protecting Access to Pain Relief Coalition officially launched on June 22 to help ensure that American consumers continue to have access to, and choice of, safe and effective pain relief, including acetaminophen.
Before Cardinal Health’s annual Retail Business conference meeting, Drug Store News spoke with the company’s SVP marketing and consumer solutions Christi Pedra and SVP Independent Retail Sales Steve Lawrence.